Pro Medicus Expands U.S. Footprint with Major BayCare Contract
Pro Medicus Limited (ASX: PME) has strengthened its position in the U.S. healthcare imaging market through a new AU$25 million, seven-year agreement with BayCare, a leading health system in Florida. The deal adds the cloud-based Visage 7 Open Archive to BayCare’s existing Visage 7 Viewer and Workflow systems, creating a complete “full-stack” imaging solution. Implementation begins immediately, with migration to the cloud and a target go-live in early 2026.
This contract highlights Pro Medicus’ growing success with its scalable, high-performance cloud technologies and reinforces the company’s opportunity to expand its Open Archive offering across North American integrated delivery networks (IDNs). Operating under a transaction-based model, the deal provides potential revenue upside over time. Founded in 1983, Pro Medicus has evolved into a global leader in advanced imaging software, supported by its Visage 7 platform and a comprehensive suite of RIS, PACS, AI, and e-health solutions.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Pro Medicus Expands U.S. Footprint with Major BayCare Contract
Pro Medicus Limited (ASX: PME) has strengthened its position in the U.S. healthcare imaging market through a new AU$25 million, seven-year agreement with BayCare, a leading health system in Florida. The deal adds the cloud-based Visage 7 Open Archive to BayCare’s existing Visage 7 Viewer and Workflow systems, creating a complete “full-stack” imaging solution. Implementation begins immediately, with migration to the cloud and a target go-live in early 2026.
This contract highlights Pro Medicus’ growing success with its scalable, high-performance cloud technologies and reinforces the company’s opportunity to expand its Open Archive offering across North American integrated delivery networks (IDNs). Operating under a transaction-based model, the deal provides potential revenue upside over time. Founded in 1983, Pro Medicus has evolved into a global leader in advanced imaging software, supported by its Visage 7 platform and a comprehensive suite of RIS, PACS, AI, and e-health solutions.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au